It was designed to evaluate the efficacy and safety of palbociclib in combination with trastuzumab with or without letrozole in treating localized advanced or metastatic ER+/HER2+ breast cancer patients who had received 2–4 prior lines of anti-HER2-based regimens. The gene discussed is ESR1; the disease is breast cancer.